Skip to content

Effect of a package of care on outcomes in patients with gout

Effect of a package of care on serum urate levels in gout patients in a rural general practice setting

Status
Completed
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12614001177640
Enrollment
68
Registered
2014-11-10
Start date
2015-01-05
Completion date
2015-10-06
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Gout is a common problem particularly in New Zealand. The majority of patients with gout are managed in primary care. Guidelines for management are well established and there are effective medications to prevent gout, but few patients achieve treatment targets, leading to painful gout attacks and eventual joint damage. We have implemented an integrated package of care, designed to be delivered in general practice that incorporates education, gout treatment and appropriate screening and management of important co-morbidities associated with gout such as heart disease and diabetes. Herein we will examine the effetcs of the package of care in a rural general practice setting, Kaikoura. We will determine whether more patients reach treatment targets and are screened for and where appropriate receive treatment for co-morbidities. Outcomes will be compared to retrospective data from the same medical practice.

Interventions

Patients with gout receive a package of care from the GP which represents best clinical practice (based on ACR and EULAR guidelines). This will include 1. medication for acute gout as well as long term urate lowering therapy - this may be no different from the historical controls other than more focus on achieving appropriate treatment targets 2. education about the causes and management of gout - unknown what the controls received 3. screening for co-morbidities associated with gout including

Patients with gout receive a package of care from the GP which represents best clinical practice (based on ACR and EULAR guidelines). This will include 1. medication for acute gout as well as long term urate lowering therapy - this may be no different from the historical controls other than more focus on achieving appropriate treatment targets 2. education about the causes and management of gout - unknown what the controls received 3. screening for co-morbidities associated with gout including heart disease, diabetes and kidney disease - unknown what the controls received. There is no specified treatment period as this is individualised The only proceedures outside of nornal clinical practice are that we will monitor whether patients take allopurinol (one form of urate lowering medication) through blood tests.

Sponsors

University of Otago
Lead SponsorUniversity

Eligibility

Sex/Gender
All
Age
0 to No maximum
Healthy volunteers
No

Inclusion criteria

Gout

Exclusion criteria

Unwilling to provide consent

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026